23 Aug 2019 The investigational antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of interleukin 1 signaling.

Cantargia Professor Ahmad Awada presenterade fas 1-resultaten för CAN04 inför en välfylld sal med hundratals åhörare. Det mest intressanta i presentation var att få se nivåsänkningarna av IL-6 och CRP, vilket är relevant då dessa biomarkörer visats korrelera med patientöverlevnad..

2021-3-19 · Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The lead project CAN04 is in phase IIa clinical development for treatment of cancer Detailed Description: CAN04 is a first-in-class fully humanized and ADCC enhanced monoclonal antibody, targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP). The CAN04 strategy is to attack the IL1RAP target molecule using an effective antibody-based cancer treatment. 2021-2-5 · Cantargia reports positive interim data from ongoing phase IIa combination study with antibody CAN04 Mon, Dec 02, 2019 10:30 CET. Cantargia AB today announced the first interim data with antibody CAN04 in combination with chemotherapy in the ongoing phase IIa CANFOUR study. Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer 2020-5-14 · Cantargia is a Swedish biotechnology company focused on developing new concepts for immunotherapeutic treatment of cancer and autoimmune / inflammatory diseases. Our development program includes the product candidate CAN04, which is in phase IIa of the clinical studies, as well as our development project CAN10.

Cantargia can04

I den USA-studie som Cantargia väntas starta senare i år kommer CAN04 kombineras med Keytruda. A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Cantargia AB meddelade idag att en ansökan lämnats in kring en klinisk studie som undersöker antikroppen CAN04 i kombination med FOLFIRINOX för första linjens behandling av metastatisk bukspottkörtelcancer (PDAC).

Cantargia's Phase IIa CANFOUR trial investigates CAN04 in a combination with a different chemotherapy (platinum-based as opposed to docetaxel in the Novartis

Antikroppen CAN04 binder IL1RAP 10 Mar 2021 Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for 23 Aug 2019 The investigational antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of interleukin 1 signaling. 27 Nov 2020 BioInvent and Cantargia have signed a manufacturing agreement for Apart from CAN10, Cantargia is developing another antibody CAN04, 17 Nov 2015 BRIEF-Cantargia selects two cancer forms as primary indications for CAN04 cancer have been selected as primary indications for CAN04.

Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer

Utifrån resultaten av fas 1-delen i studien kommer Cantargia att kunna specificera hur den fortsatta studien ska utformas och vilka substanser den då ska kombineras med.

Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). Cantargia posted a Q1 report that contained few surprises, which we take to be a positive sign that the ph IIa study for the flagship product, CAN04, is progressing according to plan. During the quarter, the company completed a directed share issue of around SEK 106m and the proceeds will enable further investments in its clinical programmes. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and 2021-4-11 · Can04, like canakinumab, is also being tested in combination with Keytruda. Its 2026 sales forecasts sit at $564m, according to EvaluatePharma ’s sellside consensus.
Orebro folkmangd

This study included 22 patients with non–small cell lung cancer (NSCLC; four patients), pancreatic ductal adenocarcinoma (six patients), or The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer.

In its most advanced program, the antibody CAN04 is being tested 10 mar 2021 Cantargia. Novartis bakslag kan inte jämföras med Cantargias Can04, är 'tydligt differentierad' från Novartis kandidat - Edison (Finwire).
John dewey pedagogik

ipc oil and gas malaysia
länsstyrelsen sörmlands län
mikael thorell
bästa aktietips 2021
pq formel uppgifter
medieprogrammet kurser

2020-3-10 · "Cantargia has focused the CAN04 development on solid tumors and the clinical data we have generated in patients with NSCLC or PDAC are encouraging. By acquiring this IP, we have secured all relevant IP on IL1RAP as a target for cancer therapy", said Göran Forsberg, CEO of Cantargia. For further information, please contact Göran Forsberg, CEO

Antikroppen CAN04 binder IL1RAP med hög affinitet och verkar både genom blockad av IL-1-signalering och s.k. Antibody-Dependent Cellular Cytotoxicity (ADCC). Prekliniska data visar att CAN04 kan öka effekten av cellgifter. CAN04 i nivå med de resultat som den nya immunomodulerande antikroppen Keytruda (pembrolizumab, Merck) nyligen visat i en fas 2-studie (KEYNOTE-799) på 216 svårt sjuka NSCLC-patienter (icke operabelt stadium III). I den USA-studie som Cantargia väntas starta senare i år kommer CAN04 kombineras med Keytruda. A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.